Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001GlobeNewsWire • 09/20/21
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021GlobeNewsWire • 08/24/21
Solid Biosciences Reports Inducement Grant to New Senior Vice President, FinanceGlobeNewsWire • 08/19/21
Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, FinanceGlobeNewsWire • 08/19/21
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial ResultsGlobeNewsWire • 08/16/21
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical DevelopmentGlobeNewsWire • 07/02/21
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular DystrophyGlobeNewsWire • 07/01/21
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory OfficerGlobeNewsWire • 06/07/21
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
Solid Biosciences Provides First Quarter 2021 Business Update and Financial ResultsGlobeNewsWire • 05/14/21
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing SummitGlobeNewsWire • 04/20/21
Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease DayGlobeNewsWire • 03/25/21
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment OptionGlobeNewsWire • 03/23/21
Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer InvestorsBenzinga • 03/16/21